At this time, however, ACIP
has not identified a preferred TIV product for this age group.
In 2007, ACIP
recommended that the quadrivalent meningococcal conjugate vaccine (MCV4), sold under the brand names Menactra and Menveo, be given to 11-to 12-year-olds at the established preteen visit, and to 13- to 18-year-olds who had not been previously vaccinated.
Rosters of current and past members of the Advisory Committee on Immunization Practices (ACIP
) are available at https://www.cdc.
Lauri Markowitz of the CDC, who presented the ACIP
recommendations for the use of the bivalent vaccine.
At the February meeting of ACIP
, the committee approved language that providers may provide any licensed, age-appropriate influenza vaccine, and LAIV4 is considered in this set of vaccine options.
For further guidance on the use of each vaccine included in the schedules, including contraindications and precautions, health care providers are referred to the respective ACIP
vaccine recommendations at https://www.cdc.gov/vaccines/hcp/acip-recs/index.html.
Immuno-oncology company Agenus Inc (NASDAQ:AGEN) stated on Wednesday that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP
) has voted in favor of three recommendations for the Shingrix (Zoster Vaccine Recombinant, Adjuvanted) vaccine with QS-21 Stimulon for the prevention of shingles (herpes zoster), a virus called varicella zoster, which is also known as the chicken pox virus.
"I think ACIP
is likely to reconsider the issue of routine meningococcal conjugate vaccine for infants in October, with a possible vote on the matter in February,'" he predicted.
This evolving epidemiology of pertussis has prompted ACIP
to recommend a routine single Tdap dose for adolescents between the ages of 11 and 18 years who have completed the recommended DTP/DTaP (diphtheria and tetanus toxoids and pertussis/diphtheria and tetanus toxoids and acellular pertussis) vaccination series and for adults ages 19 to 64 years.
A draft was prepared and presented at the ACIP
meeting, at which the changes were unanimously approved by the 14-member advisory committee.
In June 2011, the ACIP
changed its recommendation to one dose of the vaccine during pregnancy in women who had never received it before.
Cohn, who presented the draft of the recommendations at the ACIP